SecurityCFI / Culp, Inc. (230215105)
IndustryBroadwoven Fabric Mills, Cotton
Common Shares Outstanding12,450,276 shares (as of 2018-01-28)
Total Insiders10
Total Directors6
Total Officers6

Stock Insider Trading (from SEC Form 4)

Culp, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CFI / Culp, Inc. insiders include JACKSON FRED A, FLAVIN PATRICK B, SAXON FRANKLIN N, LARSON KENNETH R, Bowling Kenneth R, and CHUMBLEY BOYD BROOKS, CULP ROBERT G III, MCALLISTER KENNETH W, Gallagher Thomas Bernard JR CULP ROBERT GEORGE IV, .

Insider Roster

Insider Dir Off 10% Shares Owned
CULP ROBERT GEORGE IV President Culp Home Fashions
X 58,140
SAXON FRANKLIN N Chief Executive Officer, Director
X X 122,612
CULP ROBERT G III Chairman of the Board, Director
X X 1,232,937
CHUMBLEY BOYD BROOKS Exec VP Upholstery Fabrics
X 42,924
Bowling Kenneth R Chief Financial Officer
X 20,460
Gallagher Thomas Bernard JR Principal Accounting Officer
X 2,000
MCALLISTER KENNETH W Director
X 22,317
JACKSON FRED A Director
X 10,400
LARSON KENNETH R Director
X 11,167
FLAVIN PATRICK B Director
X 11,200

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-06-12 4 Gallagher Thomas Bernard JR M D 2,000 2,000
2018-06-12 4 Bowling Kenneth R M D 6,102 20,460
2018-06-12 4 CHUMBLEY BOYD BROOKS M D 10,185 42,924
2018-06-12 4 CULP ROBERT G III M D 17,648 1,232,937
2018-06-12 4 SAXON FRANKLIN N M D 26,424 122,612
2018-06-12 4 CULP ROBERT GEORGE IV M D 13,194 58,140
2018-01-25 4 CULP ROBERT GEORGE IV M D 7.08 15,000 47,947
2017-10-10 4 SAXON FRANKLIN N F D 31.35 -11,500 101,660
2017-10-02 4 FLAVIN PATRICK B A D 1,200 11,200
2017-10-02 4 LARSON KENNETH R A D 1,200 11,167
2017-10-02 4 JACKSON FRED A A D 1,200 10,400
2017-10-02 4 MCALLISTER KENNETH W A D 1,200 22,317
2017-06-28 4 Bowling Kenneth R F D 32.5 -3,011 14,177
2017-06-22 4 SAXON FRANKLIN N F D 32.5 -18,609 113,160
2017-06-22 4 CHUMBLEY BOYD BROOKS F D 32.5 -7,436 32,178
2017-06-26 4 CULP ROBERT GEORGE IV F D 32.5 -5,859 32,947
2017-06-12 4 CHUMBLEY BOYD BROOKS M D 15,838 39,614
2017-06-12 4 Bowling Kenneth R M D 9,137 17,188
2017-06-12 4 CULP ROBERT GEORGE IV M D 17,780 38,806
2017-06-12 4 CULP ROBERT G III M D 24,481 1,215,289
2017-06-12 4 SAXON FRANKLIN N M D 35,609 131,769
2017-06-02 4 CULP ROBERT G III Family Trust S I 34 -1,049 1,190,808 40,487,472
2017-06-02 4 SAXON FRANKLIN N S D 34 -356 96,160 3,269,440
2017-05-09 4 CULP ROBERT G III Family Trust S I 34 -2 1,191,857 40,523,138
2017-05-09 4 SAXON FRANKLIN N S D 34 -1 96,516 3,281,544
2017-05-04 4 CULP ROBERT G III Family Trust S I 34 -130 1,191,859 40,523,206
2017-05-04 4 SAXON FRANKLIN N S D 34 -44 96,517 3,281,578
2016-12-08 4 CULP ROBERT GEORGE IV S D 36 -2,500 22,626 814,536
2016-12-08 4 CULP ROBERT GEORGE IV S D 35.25 -1,361 25,126 885,692
2016-12-07 4 CULP ROBERT GEORGE IV S D 35.25 -1,139 26,487 933,667
2017-04-28 4 CULP ROBERT GEORGE IV G D 32.1 -780 21,026
2017-04-27 4 CULP ROBERT GEORGE IV G D 33.25 -820 21,806
2017-04-26 4 CHUMBLEY BOYD BROOKS 401(k) Plan S I 33.6 -1,400 23,776 798,874
2017-04-26 4 CULP ROBERT G III Family Trust S I 34 -195 1,191,989 40,527,626
2017-04-26 4 CULP ROBERT G III Family Trust S I 33.51 -12,400 1,192,184 39,950,086
2017-04-26 4 CULP ROBERT G III Family Trust S I 33 -8,856 1,204,584 39,751,272
2017-04-25 4 CULP ROBERT G III Family Trust S I 33 -3,544 1,213,440 40,043,520
2017-04-26 4 SAXON FRANKLIN N S D 34 -66 96,561 3,283,074
2017-04-26 4 SAXON FRANKLIN N S D 33.51 -4,210 96,627 3,237,971
2017-04-26 4 SAXON FRANKLIN N S D 33 -3,007 100,837 3,327,621
2017-04-25 4 SAXON FRANKLIN N S D 33 -1,203 103,844 3,426,852
2017-04-24 4 CULP ROBERT G III Family Trust S I 32.5 -3,655 1,216,984 39,551,980
2017-04-24 4 SAXON FRANKLIN N S D 32.5 -1,241 105,047 3,414,028
2017-04-21 4 CULP ROBERT G III Family Trust S I 32.5 -228 1,221,269 39,691,242
2017-04-20 4 CULP ROBERT G III Family Trust S I 32.5 -3,554 1,221,497 39,698,652
2017-04-21 4 SAXON FRANKLIN N S D 32.5 -77 106,288 3,454,360
2017-04-20 4 SAXON FRANKLIN N S D 32.5 -1,207 106,365 3,456,862
2017-04-12 4 CHUMBLEY BOYD BROOKS 401(k) Plan S I 32.35 -1,176 25,176 814,444
2017-04-12 4 CULP ROBERT G III Family Trust S I 32.5 -4,963 1,225,051 39,814,158
2017-04-12 4 CULP ROBERT G III Family Trust S I 32 -4,544 1,230,014 39,360,448
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

10h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Culp: Soft Products In A Tough Industry

2018-06-18 seekingalpha
Culp’s long-standing track record and first-rate product quality are why they have a leading market share among home-wear fabrics producers in North America. (17-0)

Culp Inc's (CULP) CEO Frank Saxon on Q4 2018 Results - Earnings Call Transcript

2018-06-14 seekingalpha
Good day and welcome to the Culp’s Fourth Quarter 2018 Earnings Conference Call. Today's conference is being recorded. At this time, for opening remarks and instructions, I'd like to turn the call over to Ms. Dru Anderson. Please go ahead ma’am. (2-0)